A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML

This is a Phase 1, open-label, multicenter, dose-escalation \& expansion study to evaluate the safety,tolerability and pharmacokinetics (PK) of LP-108, a BCL-2 inhibitor, combined with azacitidine, to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RP2D), and to assess the preliminary efficacy of this combination.

Trial Details

NCT ID
NCT05641259
Phase
PHASE1
Sponsor
Guangzhou Lupeng Pharmaceutical Company LTD.
Status
RECRUITING
Cancer Type
Acute Myeloid (AML) Leukemia
Interventions
  • LP-108
  • Azacitidine
Locations (sample)
  • Nanchang, China|28.68396,115.85306
  • Suzhou, China|31.30408,120.59538
  • Zhengzhou, China|34.75778,113.64861

Key Eligibility Criteria

  • Subject must has a diagnosis of one of the following: relapsed or refractory (R/R) or untreated ineligible for treatment with a standard induction …
  • ECOG performance status ≤ 2.
  • Estimated survival ≥ 12 weeks.
  • Baseline white blood cell count (WBC) ≤ 25 x 109/L.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Myeloid (AML) Leukemia Trials on Trialify →